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Various radiolabeled monoclonal antibodies have been
developed for the treatment and diagnosis of malignancies.
Rituximab is a chimeric mouse-human monoclonal antibody.
Rituximab selectively binds with high affinity to the CD20
antigen (human B-lymphocyte restricted differentiation antigen,
Bp35), a hydrophobic transmembrane protein, which is
expressed on B-lymphocytes and on >90% of B cell non-
Hodgkin’s lymphomas. These properties make the CD20
receptor a suitable target for radioactive therapy. 177Lu has
been considered as a promising radionuclide for developing
therapeutic radiopharmaceuticals, esp. radiolabeled
monoclonal antibodies, owing to its suitable decay
characteristics, as well as the feasibility of large-scale
production in adequate specific activity and radionuclidic
purity.
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In order to obtain 177Lu anti-CD20 radioimmunoconjugates
for using in therapeutic studies, different bifunctional
chelating agents-antiCD20 (rituximab) (BFCA-rituximab)
were labeled by “cold” 177Lu chloride for preliminary
chemical characterization (Figure 1).
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MALDI-TOF experiments revealed the presence of two
major peaks corresponding to a MW of conjugated and
unconjugated rituximab equivalent to an average of 7.7 (p-
SCN-Bn-DOTA), 11 (p-SCN-Bn-DTPA) and 9.8 (1B4M-
DTPA) groups per molecule of antibody (Figure 2).
All three BFCA-rituximab conjugates (labeled and non-
labeled) were resolved in two distinct Mr species which
migrated in two bands (upper band at ~50 kDa and lower
band ~30 kDa) confirming the migration behavior typical for
IgG antibodies which are composed of two identical subunits
each composed by two polypeptide chains: two heavy and
two light chains, linked via disulfide bonds (Figure 3).
Results of this study showed that “cold” labeling of the
lyophilized formulation (kit) of BFCA-rituximab results in
immunoconjugates with good purity and stability.
Findings of this study suggest that further investigations may
result in a lyophilized (kit) formulation which could be easily
radiolabeled with 177Lu in order to be used for
radioimmunotherapy of patients with relapsed and refractory
non Hodgkin's lymphoma.
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p-SCN-Bn-DOTA [2-(4-
Isothiocyanatobenzyl)-1,4,7,10-
tetraazacyclododecane-tetraacetic acid]
p-SCN-Bn-DTPA [2-(4-
Isothiocyanatobenzyl)-
diethylenetriaminepentaacetic acid]
1B4M-DTPA [2-(4-
isothiocyanatobenzyl)-6-methyl-
diethylenetriaminepentaacetic acid]
+
freeze-dried preparation 
dissolved with sterile saline, and labelled with 1.0709 µg Lu chloride
Incubation 
• 30 min at room temperature (p-SCN-Bn-DTPA-rituximab and 1B4M-DTPA-rituximab) 
• 60 min at 40 C (p-SCN-Bn-DOTA-rituximab)
Characterization of the conjugated BFCA-MoAb and
determination of the average number of BFCA attached to
each antibody molecule was performed by Matrix-Assisted
Laser Desorption Ionization time-of-flight (MALDI-TOF) mass
spectrometry. 10 µL of the solution of the conjugated BFCA-
MoAb is diluted (1:10) with a matrix solution of 3,5-
dimethoxy-4-hydroxycinnamic acid to a concentration of
about 10 pmol/μL. An aliquot (1-2 μL) of the final solution is
applied to the sample target prior to insertion into the high
vacuum chamber of a mass spectrometer (Voyager-De
MALDI-ToF, Applied Biosystems).
In order to examine relevant quality parameters, including
detection, and purity assessment, SDS-PAGE experiments,
under reducing conditions, were performed.
Fig. 1: Schematic process of conjugation and labeling of three BFCA-rituximab
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Fig. 2: MALDI-TOF results for three BFCA-rituximab (1: p-SCN-Bn-DOTA; 2: p-
SCN-Bn-DTPA and 3: 1B4M-DTPA) 
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Fig. 3: SDS-PAGE 
paterns for three BFCA-
rituximab
(1: p-SCN-Bn-DOTA; 
2: p-SCN-Bn-DTPA;
3: 1B4M-DTPA; 
4: p-SCN-Bn-DOTA-Lu;   
5: p-SCN-Bn-DTPA-Lu 
and 6: 1B4M-DTPA-Lu; 
M is molecular marker) 
